Screener
Vertex Pharmaceuticals VRTX EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Vertex Pharmaceuticals’s reported figures.
The source filing: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000875320-26-000173
FAQ
- What is Vertex Pharmaceuticals's EBITDA?
- Vertex Pharmaceuticals (VRTX) reported EBITDA of $1.19B in Q1 2026.
- How has Vertex Pharmaceuticals's EBITDA changed year-over-year?
- Vertex Pharmaceuticals's EBITDA increased by 76.0% year-over-year, from $678.5M to $1.19B.
- What is the long-term trend for Vertex Pharmaceuticals's EBITDA?
- Over 4 years (2021 to 2025), Vertex Pharmaceuticals's EBITDA has grown at a 10.8% compound annual growth rate (CAGR), from $2.91B to $4.38B.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Vertex Pharmaceuticals's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude